Fulgent Genetics (FLGT) Earnings Dates, Call Summary & Reports

Compare

1,641 Followers

Earnings Data

Report Date

May 01, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.39

Last Year’s EPS

0.04

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 27, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call presented a mix of clear operational and strategic progress alongside meaningful near-term headwinds. Highlights include double-digit FY revenue growth (14%), robust segment growth in biopharma and diagnostics, strong margin performance in 2025, product/regulatory achievements (RNA-integrated WGS, ultra-rapid WGS, New York approvals), roll-out of an in-house digital pathology/AI platform (Ezeopath) and encouraging clinical-stage progress (FID-7 Phase 2 completion, FID-22 dose escalation). Offsetting these positives are the substantial near-term impact from the largest customer bringing volume in-house (approx. $59M estimated revenue loss), widening GAAP losses and an adjusted EBITDA loss in Q4, higher operating expenses and one-time charges, guidance for a widened 2026 non-GAAP operating loss (~-18%) and an expected non-GAAP EPS loss (-$1.45), and timing uncertainty from a delayed $106M tax refund. Management emphasizes that acquisitions (Bako/StrataDx), product innovation, AI/digital investments and a strong cash position are expected to offset the loss over time, but the first half of 2026 is expected to be pressured. Overall, the call balances meaningful strategic momentum and a strong balance sheet against significant short-term execution and margin challenges.

Company Guidance

The company guided to approximately $350 million of revenue for FY2026 (about 8.5% growth versus $322.7M in 2025), with H1 revenue ~ $158–159M and H2 ~ $191–192M (back‑end loaded); guidance assumes the largest 2025 customer’s revenue falls from $70.8M to about $11.8M (≈$59M decline) and that the pending Bako/StrataDx acquisitions contribute roughly $50–55M (purchase price ~ $55–56M), such that excluding the largest customer and assuming closing, net growth would be ~31% and no single customer would exceed 10% of revenue. By segment, anatomic pathology revenue is expected to rise to ~$162M (up ~53% from $106M), biopharma revenue to fall to ~$20M (from $25.8M), non‑GAAP gross margin is expected to be slightly above 40% for the year (with a ~4‑point Q1 headwind, ~2‑point Q2 headwind, and >41% in Q3–Q4), non‑GAAP operating margin is expected to widen to about –18% (from –8%), full‑year non‑GAAP EPS is guided to a loss of $1.45 per share (avg. 32M shares, excluding stock‑based comp, impairment, acquisition costs and amortization), therapeutic development spend is forecast at ~$26M, capex ~$12M, a one‑time professional liability of ~$14.5M is assumed, and year‑end cash is projected at roughly $606M–$685M assuming receipt of a delayed $106M tax refund.

Full-Year Revenue Growth

Total revenue for FY2025 was $322.7M, up approximately 14% year-over-year.

Quarterly and Segment Strength

Q4 2025 revenue was $83.3M (Brandon: +9% YoY, slight QoQ decline). Segment Q4 performance: Precision Diagnostics $48.2M (+11% YoY, -5% QoQ), Anatomic Pathology (AP) $27.0M (+3% YoY, +4% QoQ), Biopharma Services $8.1M (+32% YoY, +10% QoQ). Full-year segment growth: Precision Diagnostics $190.5M (+14% YoY), AP $106.4M (+10% YoY), Biopharma Services $25.8M (+58% YoY).

Gross Margin Expansion

Non-GAAP gross margin in Q4 was 41% (GAAP 39.1%). Management cites FY2025 margin improvement driven by streamlined operations and lab efficiencies; guidance expects full-year 2026 non-GAAP gross margins slightly above 40% with H2 recovery after a 1H headwind.

Product and Platform Innovations

Launched RNA-integrated whole genome sequencing and ultra-rapid whole genome sequencing; proprietary imaging management system (Ezeopath/EZOPAS) rolled out and company reports ~100% digital case reading on the platform; multiple in-house and third-party AI modules launched and a pipeline of a dozen AI modules planned for 2026.

Regulatory Approvals

New York State approvals received in Q4 for proprietary NIPT offering (Nova) and whole genome sequencing test, enabling commercialization in a large market.

M&A to Reduce Customer Concentration

Announced intended acquisition of Bako Diagnostics and StrataDx for ~$55.5M (expected close in March 2026). Management expects the acquisitions to contribute ~$50M–$55M revenue in 2026 and to reduce any single-customer concentration to <10% of revenue.

Therapeutics Pipeline Progress

FID-7 completed Phase 2 enrollment (46 patients) with encouraging early efficacy/safety; Phase 3 protocol development underway with potential 2027 start and an interim ASCO presentation expected June 2026. FID-22 progressing in Phase 1 dose escalation with dose levels advancing (third dose started 02/02/2026) and MTD expected later in 2026.

Strong Liquidity Position

Cash, cash equivalents, restricted cash and marketable securities were approximately $755.5M at year-end; management forecasts year-end 2026 cash of ~$606M–$685M assuming receipt of a delayed $106M tax refund and closing of acquisitions.

Fulgent Genetics (FLGT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FLGT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 01, 2026	2026 (Q1)	-0.39 / -	0.04	―	―	―
Feb 27, 2026	2025 (Q4)	0.03 / 0.16	0.04	300.00% (+0.12)
Nov 07, 2025	2025 (Q3)	-0.22 / 0.14	0.31	-54.84% (-0.17)
Aug 01, 2025	2025 (Q2)	-0.18 / 0.07	0.15	-53.33% (-0.08)
May 02, 2025	2025 (Q1)	-0.18 / 0.04	-0.01	500.00% (+0.05)	―
Feb 28, 2025	2024 (Q4)	-0.12 / 0.04	0.28	-85.71% (-0.24)	―
Nov 08, 2024	2024 (Q3)	-0.15 / 0.31	-0.39	179.49% (+0.70)
Aug 02, 2024	2024 (Q2)	-0.30 / 0.15	-0.08	287.50% (+0.23)
May 03, 2024	2024 (Q1)	-0.32 / -0.01	-0.22	95.45% (+0.21)
Feb 28, 2024	2023 (Q4)	-0.29 / 0.28	-0.48	158.33% (+0.76)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FLGT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 27, 2026	$24.76	$15.33	-38.09%
Nov 07, 2025	$22.31	$26.36	+18.15%
Aug 01, 2025	$17.18	$18.53	+7.86%
May 02, 2025	$17.25	$20.54	+19.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fulgent Genetics (FLGT) report earnings?

Fulgent Genetics (FLGT) is schdueled to report earning on May 01, 2026, After Close (Confirmed).

What is Fulgent Genetics (FLGT) earnings time?

Fulgent Genetics (FLGT) earnings time is at May 01, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FLGT EPS forecast?

FLGT EPS forecast for the fiscal quarter 2026 (Q1) is -0.39.